COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”

DiME (Digi MarketEr):-TiME to SHiNE

The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

Brecht Vanneste has been appointed as Managing Director of MSD India

He steps into the role with a clear mandate...

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Marketing

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

Brecht Vanneste has been appointed as Managing Director of MSD India

He steps into the role with a clear mandate...

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Policies/Sales

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

Brecht Vanneste has been appointed as Managing Director of MSD India

He steps into the role with a clear mandate...

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Strategy

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

Brecht Vanneste has been appointed as Managing Director of MSD India

He steps into the role with a clear mandate...

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Digital as Emergent Strategy – Lessons for Pharma from Honda

The door to the magical realm is open! Are...

Digital in Pharma and RoI – What and How to Measure Metrics that Matter

To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.